Food and Drug Administration

IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries

Retrieved on: 
Friday, April 5, 2024
HMO, Pressure, Patient, Food and Drug Administration, Health care, Safety, Interim, Clalit Health Services, FDA, Health, Food

PressureSafe™ uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin color agnostic detection of pressure injuries with real-time analysis at the point of care.

Key Points: 
  • PressureSafe™ uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin color agnostic detection of pressure injuries with real-time analysis at the point of care.
  • In the U.S. alone, 60,000 patients die every year as a direct result of pressure injuries.
  • Patient care cost per pressure injury ranges from $20,900 up to $151,700, for the 2.5 million patients per year who develop pressure injuries.
  • Pressure injuries are one of the five most common harms experienced by patients and the second most common claim for lawsuits after wrongful death.

InMode Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 15, 2024 to Discuss Your Rights – INMD

Retrieved on: 
Thursday, April 4, 2024
Telephone, Food and Drug Administration, LLP, CLASS, NEXT, COST, FDA, Court, Food, Cryptocurrency

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in InMode Ltd. ("InMode" or the "Company") (NASDAQ: INMD) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in InMode Ltd. ("InMode" or the "Company") (NASDAQ: INMD) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of InMode investors who were adversely affected by alleged securities fraud between June 4, 2021 and October 12, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    INMD investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of InMode

Retrieved on: 
Wednesday, April 3, 2024
Food and Drug Administration, LLP, Confidentiality, Injury, Advertising, FDA, Court

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding InMode’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

InMode Ltd. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 15, 2024 to Discuss Your Rights – INMD

Retrieved on: 
Wednesday, April 3, 2024
NEXT, Fraud, Food and Drug Administration, FDA, Food, Security (finance)

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of InMode Ltd. (NASDAQ: INMD).

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of InMode Ltd. (NASDAQ: INMD).
  • Shareholders who purchased shares of INMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NYCB, InMode, Innodata, and Fox Factory and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 3, 2024
Research, Class Action, Signature, Growth, ACL, Food and Drug Administration, Defendant, Dermatology, News, AI, New York Community Bank, Nature, NYCB, Silicon, Complaint, P.C, Goldengate, Research and development, Fox Factory, Assumption, Confidentiality, Injury, Category, Wolfpack, Dentist, FDA, Marketing

NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.

Key Points: 
  • NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.
  • On January 31, 2024, before the market opened, NYCB announced its fiscal fourth quarter 2023 financial results.
  • The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
  • For more information on the Fox Factory class action go to: https://bespc.com/cases/FOXF

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

Retrieved on: 
Wednesday, April 3, 2024
Tafenoquine, Food and Drug Administration, Infection, Food, FDA, Babesiosis, Dog, Malaria

WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company will sponsor a pilot study of tafenoquine, the active molecule in its U.S. Food and Drug Administration (FDA)-approved human malaria prevention medication, ARAKODA®, for the treatment of babesiosis in dogs.

Key Points: 
  • WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company will sponsor a pilot study of tafenoquine, the active molecule in its U.S. Food and Drug Administration (FDA)-approved human malaria prevention medication, ARAKODA®, for the treatment of babesiosis in dogs.
  • The study will support a broader effort now being led by 60 Degrees Pharmaceuticals to evaluate tafenoquine for various babesiosis indications.
  • Tafenoquine has not been proven to be effective for treatment or prevention of canine babesiosis and is not approved by the FDA for such an indication.

INMD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that InMode Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Wednesday, April 3, 2024
Food and Drug Administration, Dermatology, Complaint, Confidentiality, Injury, Dentist, FDA, Court, Person

InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BLUEBIRD BIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (NASDAQ: BLUE)

Retrieved on: 
Tuesday, April 2, 2024
Sickle cell disease, Blue, District court, Patient, Food and Drug Administration, News, Cancer, Complaint, Action Replay, Food, FDA, Court, Advertising, Bluebird bio, Security (finance)

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action – INMD

Retrieved on: 
Tuesday, April 2, 2024
Titan, Food and Drug Administration, Class, Advertising, FDA, Court, Food

WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

INMD STOCKHOLDER ALERT: Robbins LLP Reminds Investors of Quickly Approaching Lead Plaintiff Deadline – April 15, 2024 – in the InMode Ltd. Class Action

Retrieved on: 
Tuesday, April 2, 2024
SAN, Food and Drug Administration, FDA, Confidentiality, News, LLP

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of purchasers of InMode Ltd. (NASDAQ: INMD) common stock between June 4, 2021 and October 12, 2023.

Key Points: 
  • SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of purchasers of InMode Ltd. (NASDAQ: INMD) common stock between June 4, 2021 and October 12, 2023.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • The customers also stated that InMode offered to replace defective products on the condition of signing confidentiality agreements with non-disparagement clauses.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.